Search results
Results from the WOW.Com Content Network
Wang noted that SHINE is the first phase 3 study to examine ibrutinib plus BR as a first-line therapy in mantle cell lymphoma and involved patients with previously untreated stage II-IV disease ...
Maddocks: I do think that's fair. I think in the StiL trial, having mantle cell lymphoma was a negative prognostic indicator overall. But really in both trials, it did seem to be that mantle cell ...
Actually, mantle cell lymphoma was only acknowledged as a separate lymphoma entity in 1994. The group had started trials in 1996, and there was not much research done before that time. So I could ...
This drug is the first BTK inhibitor approved to treat mantle cell lymphoma in this setting. Approval was based on overall response rates and duration of response in the phase 1/2 BRUIN trial.
Mantle cell lymphoma has always been a particular interest of mine. I remember seeing some cases of mantle cell lymphoma as a fellow. This was about 25 years ago, and it was a fairly recently ...
Mantle cell lymphoma (MCL) can run the gamut from an indolent to aggressive disease, and identifying biomarkers is key in determining which patients should follow a watch-and-wait strategy and ...
Hsi: In situ mantle cell lymphoma is diagnosed when there's an incidental finding in a lymph node biopsy. You're just standardly working up your case and you do a cyclin D1 stain and then you see ...
"Mantle cell lymphoma is a rare disease, which has made it a challenge to study in clinical trials, but rapid advances have been achieved in the past 2 decades, and the future is very bright ...
The beginning of the end for upfront stem cell transplants and chemotherapy, plus novel relapsed/refractory therapies, are among Dr Peter Martin's highlights in mantle cell lymphoma from ASH 2022.
An Impactful Patient Experience That Has Altered My Approach to Mantle Cell Lymphoma 2001/viewarticle/986707 Analyzing Disparities in the Treatment of Mantle Cell Lymphoma